Space-driven drug development is a field of study that uses outer space's unique properties, such as microgravity, cosmic radiation, and the vacuum environment, to accelerate and enhance pharmaceutical drug development. Such habitats provide a unique chance to investigate biological and chemical processes that are not possible on Earth. Microgravity changes how crystal structures form, yielding better samples than those produced on Earth. Improving the 3D structure might have a positive impact on pharmaceutical distribution, manufacture, and storage. The findings might lead to better medication development, formulations, and innovative therapy for a number of conditions.
 

Space-driven Drug Development

Liquid-liquid separation and chemical extraction are key processes in medicine and many other industries, such as oil and gas, fragrances, food, wastewater purification, and biotechnology.
In space, microgravity allows materials to develop without encountering obstacles, as well as mix uniformly and stay together without the requirement of conventional supports. A nearby ultra-high vacuum also promotes the production of impurity-free materials. Crystals can grow larger in microgravity; in one experiment, protein crystals reached an average size of 6 cubic millimetres, compared to 0.5 cubic millimetres on Earth. Once created, the crystals may be studied to show the proteins' 3D architectures, which can aid in future medication development efforts.

​

1.  Target Identification and Validation: In microgravity, researchers can study the effects of altered gravity on biological systems, which may reveal new biochemical pathways and mechanisms that are not observable on Earth. For instance, NASA has compiled extensive data on how microgravity influences gene expression and cellular signalling, which can lead to the identification of novel drug targets for various diseases.

2. Protein Crystallization: The microgravity environment reduces disturbances such as convection currents and sedimentation that can affect crystal growth on Earth. This allows for larger and more well-ordered protein crystals to form, which are essential for X-ray crystallography. High-quality crystal structures enable more accurate drug design by providing detailed information about the target protein's structure and how potential drugs interact with it.

3. Non-Clinical In Vivo Studies: The ISS has been used to study the effects of micrgravity on animal models, particularly regarding muscle and bone health. Research has shown that astronauts experience muscle atrophy and bone density loss during long-duration space flights. Various candidate drugs, including anti-resorptive agents and anabolic agents, are being tested in these models to evaluate their efficacy in mitigating these effects, which could also have applications for treating osteoporosis and muscle wasting on Earth.

4. Drug Stability: Medications may behave differently in space due to factors like radiation exposure and the μG environment, which can affect their stability and efficacy. Research has shown mixed results regarding drug degradation in space, with some studies indicating that certain drugs may degrade faster than on Earth while others maintain their potency. Ongoing studies aim to optimize drug formulations and packaging to ensure their effectiveness during long missions.

5. Immune Response and Drug Resistance: Spaceflight has been shown to suppress immune function, with studies indicating changes in leukocyte distribution and reduced T cell activity. This poses challenges for treating infections in space, as pathogens may exhibit altered virulence under microgravity conditions. Research into how bacteria, such as E. coli, adapt to space environments has revealed increased resistance to antibiotics, necessitating the development of new therapeutic strategies.

 

Scope and Relevance 

The concept of performing drug research in space is more than a science fiction fantasy; it is a fast-expanding subject that has the potential to transform the landscape of healthcare and pharmaceuticals. While space research has had its share of obstacles and expenditures, the future of space-based medical development seems promising.  The microgravity environment is ideal for developing high-quality crystals because it decreases sedimentation, allows for precise regulation of temperature, and produces smaller, more homogeneous particles.

 

Looking ahead, NASA intends to increase its space-based resources in partnership with the private sector, potentially establishing a thriving space economy. The construction of commercially developed outposts intends to assist many types of research, including biomedical investigations.

 

While there are presently only a few companies engaging in space-based research, pharmaceutical giants such as Bristol Myers Squibb, Amgen, Merck Life Science, and Gilead Sciences are showing an increasing interest. LambdaVision, Inc., a space-bio corporation, is also leveraging this unique environment for initiatives like developing artificial retinas. Aside from well-known pharmaceutical companies, there is an increasing number of startups actively involved in space-based medication development research. SpaceTech businesses such as Space Tango, SpacePharma, Varda Space Industries, ResearchSat, and others are committed to providing cost-effective options for performing drug development research in space.

 

Disease is an inevitable component of being alive, thus disease prevention, diagnosis, and treatment will be crucial for human deep space missions. Pharmaceuticals are used to diagnose, treat, cure, or prevent disease, but they are unstable on Earth and especially in space. What if modest quantities of medications could be produced in space, on-site, and on demand? The biopharmaceutical or 'biologic' class of treatments (peptide or protein medications) would be especially well suited to space manufacture. Many of the medical illnesses and crises that astronauts have or are anticipated to experience may be properly treated with these medications.